Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023

2008569 citationsJournal Articlebronze Open Access

Authors

In this unselected population, gefitinib did not improve survival. Decreased survival was a result of tumor progression and not gefitinib toxicity.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 26, Issue 15, pp. 2450-2456

Field-Weighted Citation Impact: 38.79